News in brief - June 2014 (updated)

Other new launches, licence changes and updates relevant to general practice.

Noxafil is not recommended in children under 18 years of age.
Noxafil is not recommended in children under 18 years of age.
  • The antifungal Noxafil (posaconazole) is now available as a 100mg gastroresistant tablet. Owing to differences in dosing, the tablets and the existing 40mg/ml oral suspension cannot be used interchangeably.
  • Updated prescribing information for Betmiga (mirabegron) states that it should be prescribed with caution in patients with clinically significant bladder outlet obstruction and those taking antimuscarinic medications for overactive bladder.
  • The licensed indications for Nexavar (sorafenib) have been extended to include the treatment of progressive, locally advanced or metastatic, differentiated thyroid carcinoma refractory to radioactive iodine.
  • Budenofalk (budesonide) granules can now be prescribed for the induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum and/or the ascending colon, providing an alternative formulation to Budenofalk capsules in this indication.
  • Meda has launched Treclin, a topical combination gel containing clindamycin 1% and tretinoin 0.025% for the treatment of moderate to severe acne vulgaris when comedones, papules and pustules are present.
  • Voncento (human coagulation factor VIII/human von Willebrand factor) has been launched for the prophylaxis and treatment of haemorrhage in patients with haemophilia A and in those with von Willebrand disease when desmopressin treatment alone is ineffective or contraindicated.
  • Sirturo (bedaquiline) is a new antimycobacterial approved for use in combination with at least three other drugs for pulmonary multidrug-resistant tuberculosis.
  • Defitelio (defibrotide) is the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients undergoing haematopoietic stem cell transplantation.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in